

Myanmar

Tuberculosis profile

Population 2018

54 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	181 (119–256)	338 (222–477)
HIV-positive TB incidence	15 (10–22)	29 (19–41)
MDR/RR-TB incidence ^{oo}	11 (7.4–16)	21 (14–30)
HIV-negative TB mortality	21 (12–31)	39 (23–58)
HIV-positive TB mortality	3.7 (2.5–5.2)	6.9 (4.6–9.7)

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	4.9% (4.7–5.1)
Previously treated cases	20% (19–21)

TB case notifications, 2018

Total new and relapse	137 972
- % tested with rapid diagnostics at time of diagnosis	42%
- % with known HIV status	89%
- % pulmonary	91%
- % bacteriologically confirmed ^{ooo}	44%
- % children aged 0–14 years	19%
- % women	29%
- % men	52%
Total cases notified	139 518

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	76% (54–120)
TB patients facing catastrophic total costs, 2015	60% (56–63)
TB case fatality ratio (estimated mortality/estimated incidence), 2018	14% (8–22)

TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	10 516	9%
- on antiretroviral therapy	7 464	71%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	92%
- Previously treated cases	84%
Laboratory-confirmed cases*	MDR/RR-TB: 3 479, XDR-TB: 35
Patients started on treatment**	MDR/RR-TB: 2 650, XDR-TB: 29
MDR/RR-TB cases tested for resistance to second-line drugs	927

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	87%	126 746
Previously treated cases, excluding relapse, registered in 2017	78%	1 638
HIV-positive TB cases registered in 2017	73%	10 294
MDR/RR-TB cases started on second-line treatment in 2016	79%	2 512
XDR-TB cases started on second-line treatment in 2016	63%	8

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	15%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	3.1% (2.8–3.4)

TB financing, 2019

National TB budget (US\$ millions)	62
Funding source: 3% domestic, 60% international, 37% unfunded	

^o Ranges represent uncertainty intervals


^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^{ooo} Calculated for pulmonary cases only


* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


(Rate per 100 000 population per year)




(Rate per 100 000 population per year)



Notified cases by age group and sex, 2018



Treatment success rate (%)



Total budget (US\$ millions)

